Synthesis and cancer cell cytotoxicity of substituted xanthenes

Rajan Giri, John R. Goodell, Chenguo Xing, Adam Benoit, Harneet Kaur, Hiroshi Hiasa, David M. Ferguson

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N,N-diethyl]-9-hydroxy-9-(3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 μM across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e.g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring.

Original languageEnglish (US)
Pages (from-to)1456-1463
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume18
Issue number4
DOIs
StatePublished - Feb 15 2010

Fingerprint

Xanthenes
Cytotoxicity
Cells
Cell growth
Acridines
Pyrans
Neoplasms
Type II DNA Topoisomerase
Structure-Activity Relationship
Growth
HeLa Cells
Antineoplastic Agents
Inhibitory Concentration 50
Conformations
Assays
Cell Line
DNA

Keywords

  • Cancer cells
  • Cytotoxicity
  • DNA binding
  • DU-145
  • Drug design
  • HeLa
  • Intercalation
  • MCF-7
  • Molecular modeling
  • SAR
  • Topoisomerase
  • Xanthene
  • Xanthone

Cite this

Synthesis and cancer cell cytotoxicity of substituted xanthenes. / Giri, Rajan; Goodell, John R.; Xing, Chenguo; Benoit, Adam; Kaur, Harneet; Hiasa, Hiroshi; Ferguson, David M.

In: Bioorganic and Medicinal Chemistry, Vol. 18, No. 4, 15.02.2010, p. 1456-1463.

Research output: Contribution to journalArticle

Giri, Rajan ; Goodell, John R. ; Xing, Chenguo ; Benoit, Adam ; Kaur, Harneet ; Hiasa, Hiroshi ; Ferguson, David M. / Synthesis and cancer cell cytotoxicity of substituted xanthenes. In: Bioorganic and Medicinal Chemistry. 2010 ; Vol. 18, No. 4. pp. 1456-1463.
@article{b4d513d33c2341a4a1e0248c66065762,
title = "Synthesis and cancer cell cytotoxicity of substituted xanthenes",
abstract = "A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N,N-diethyl]-9-hydroxy-9-(3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 μM across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e.g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring.",
keywords = "Cancer cells, Cytotoxicity, DNA binding, DU-145, Drug design, HeLa, Intercalation, MCF-7, Molecular modeling, SAR, Topoisomerase, Xanthene, Xanthone",
author = "Rajan Giri and Goodell, {John R.} and Chenguo Xing and Adam Benoit and Harneet Kaur and Hiroshi Hiasa and Ferguson, {David M.}",
year = "2010",
month = "2",
day = "15",
doi = "10.1016/j.bmc.2010.01.018",
language = "English (US)",
volume = "18",
pages = "1456--1463",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Synthesis and cancer cell cytotoxicity of substituted xanthenes

AU - Giri, Rajan

AU - Goodell, John R.

AU - Xing, Chenguo

AU - Benoit, Adam

AU - Kaur, Harneet

AU - Hiasa, Hiroshi

AU - Ferguson, David M.

PY - 2010/2/15

Y1 - 2010/2/15

N2 - A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N,N-diethyl]-9-hydroxy-9-(3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 μM across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e.g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring.

AB - A series of substituted xanthenes was synthesized and screened for activity using DU-145, MCF-7, and HeLa cancer cell growth inhibition assays. The most potent compound, 9g ([N,N-diethyl]-9-hydroxy-9-(3-methoxyphenyl)-9H-xanthene-3-carboxamide), was found to inhibit cancer cell growth with IC50 values ranging from 36 to 50 μM across all three cancer cell lines. Structure-activity relationship (SAR) data is presented that indicates additional gains in potency may be realized through further derivatization of the compounds (e.g., the incorporation of a 7-fluoro substituent to 9g). Results are also presented that suggest the compounds function through a unique mechanism of action as compared to that of related acridine and xanthone anticancer agents (which have been shown to intercalate into DNA and inhibit topoisomerase II activity). A structural comparison of these compounds suggests the differences in function may be due to the structure of the xanthene heterocycle which adopts a nonplanar conformation about the pyran ring.

KW - Cancer cells

KW - Cytotoxicity

KW - DNA binding

KW - DU-145

KW - Drug design

KW - HeLa

KW - Intercalation

KW - MCF-7

KW - Molecular modeling

KW - SAR

KW - Topoisomerase

KW - Xanthene

KW - Xanthone

UR - http://www.scopus.com/inward/record.url?scp=75849127526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849127526&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.01.018

DO - 10.1016/j.bmc.2010.01.018

M3 - Article

C2 - 20129790

AN - SCOPUS:75849127526

VL - 18

SP - 1456

EP - 1463

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 4

ER -